Stifel Nicolaus analyst Rick Wise has maintained their bullish stance on AORT stock, giving a Buy rating today.
Rick Wise has given his Buy rating due to a combination of factors that suggest a positive outlook for Artivion despite recent challenges. The company experienced a setback due to a cybersecurity breach that impacted sales in the fourth quarter of 2024 and is expected to affect the first quarter of 2025 as well. However, Artivion’s management anticipates a recovery and acceleration in sales growth throughout 2025, with projected revenues between $420 million and $435 million, representing a 10%-14% increase.
Additionally, the company has strong demand in its tissue business, which is expected to recover the lost sales from the cyber incident. The recent approval of the AMDS humanitarian-device-exemption is also expected to contribute positively to the company’s top-line growth in 2025. Furthermore, the anticipated approval of BioGlue in China is projected to enhance growth in the Surgical Sealants division. These factors, combined with Artivion’s comprehensive aortic repair portfolio, make the stock an attractive option for long-term investors, despite short-term pressures from the cyber incident.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $33.00 price target.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AORT in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com